louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03303404: 24-hour Blood Pressure Measurements and Ischemic Conditioning
Official title: 24-hour Blood Pressure Measurements and Ischemic Conditioning
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Blood Pressure
Lead sponsor: University of Texas at Austin
Sponsor class: OTHER
First posted: 2017-10-06
Enrollment: 22
Sex: ALL
Minimum age (years): 30
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: To determine if 24-hr ambulatory blood pressure monitoring effects endothelial function, we will measure flow-mediated dilation before and after the blood pressure monitoring (ischemia conditioning).

Detailed description: Reestablishing blood flow (reperfusion) to organs that had their blood supply restricted (ischemia) can cause damage to the vasculature via injury and tissue death resulting in endothelial dysfunction. This ischemia-reperfusion (blood flow occlusion and resupply) triggered injury can be reduced or prevented by preceding brief periods of ischemia called preconditioning. Properly-performed preconditioning can exert a powerful protection against a subsequent sustained period of ischemia in a variety of organs in the body including the heart, kidney, and skeletal muscle. Preconditioning protocol involves repeated brief inflation and deflation of a blood pressure cuff. In many of human cardiovascular research studies, it is common to measure endothelial function and ambulatory (24-hour) blood pressure. The ambulatory blood pressure device takes repeated blood pressure readings every 15-30 minutes during the daytime and 30-60 minutes at night. It is possible that repeated bouts of inflation/deflation of the blood pressure cuff could induce preconditioning effects and influence endothelial function. Therefore, in the proposed study we aim to address this hypothesis.

Eligibility criteria: Inclusion Criteria:

Adults aged between 30 to 60 years old.

Exclusion Criteria:

Exclusion from the study may be due to: i) pregnancy (by asking the subjects when the last time she had menstruation; we do have simple testing kits available if a subject is unsure about her status); ii) a recent illness, recent surgery, or any medical intervention in the 48 hours before any of the study days; iii) personal history of diabetes (fasting blood glucose \> 126 mg/dL), heart disease, or other cardiovascular problems.

Primary outcomes:
measure: Change From Baseline in Flow Mediated Dilation After 24 Hour Ischemic Conditioning With Blood Pressure Cuff
timeFrame: Baseline, Post 24 hour conditioning
Secondary outcomes:
Other outcomes:
Locations:
city: Austin
country: United States
facility: Dr. Hirofumi Tanaka
state: Texas
Study officials:
References:
citation: Fico BG, Zhu W, Tanaka H. Does 24-h ambulatory blood pressure monitoring act as ischemic preconditioning and influence endothelial function? J Hum Hypertens. 2019 Nov;33(11):817-820. doi: 10.1038/s41371-019-0214-y. Epub 2019 Jun 27.
Clinical trial NCT02007304: Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Vascular Function
Official title: Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Preventing Arterial Stiffening Effects Induced by Acute and Chronic Eccentric Exercise
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-12-10
Enrollment: 48
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of is to determine the preventive effects of Chinese herb supplement with panax ginseng and salvia miltiorrhiza prior to eccentric resistance exercise on arterial stiffness and vascular reactivity by using a double-blind randomized control design and to examine the effects of a 12-week progressive eccentric resistance exercise training on arterial elasticity and vascular reactivity, and whether a long-term supplementation would ameliorate arterial stiffening effects elicited by exercise-induced inflammation and improve endothelial function.


Eligibility criteria: Inclusion Criteria:

-Healthy sedentary adults

Exclusion Criteria:

* obesity (BMI \>30 kg/m2)
* smoking within past six months
* hypertension (high blood pressure \>140/90 mmHg)
* personal history of diabetes (fasting blood glucose \>126 mg/dL), heart disease, or other cardiovascular problems
* orthopedic injury that may prevent him or her from completing the exercise
* the use of over-the-counter supplements or vitamins

Primary outcomes:
measure: Pulse Wave Velocity
timeFrame: Before eccentric exercise and training
measure: Pulse Wave Velocity
timeFrame: 6th week of eccentric exercise traininig
measure: Pulse Wave Velocity
timeFrame: 12th week of eccentric exercise training
Secondary outcomes:
measure: Blood pressure
timeFrame: Before intervention
measure: Blood pressure
timeFrame: 6th week of intervention
measure: Blood pressure
timeFrame: 12th week of intervention
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University
Study officials:
affiliation: National Taiwan University
name: Hsin-Fu Lin, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lin HF, Chou CC, Chao HH, Tanaka H. Panax ginseng and Salvia miltiorrhiza supplementation during eccentric resistance training in middle-aged and older adults: A double-blind randomized control trial. Complement Ther Med. 2016 Dec;29:158-163. doi: 10.1016/j.ctim.2016.10.003. Epub 2016 Oct 11.
citation: Lin HF, Tung K, Chou CC, Lin CC, Lin JG, Tanaka H. Panax ginseng and salvia miltiorrhiza supplementation abolishes eccentric exercise-induced vascular stiffening: a double-blind randomized control trial. BMC Complement Altern Med. 2016 Jun 6;16:168. doi: 10.1186/s12906-016-1139-4.
Clinical trial NCT00946504: To Demonstrate the Relative Bioequivalency Comparing Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets
Official title: A Two-Way Crossover Bioequivalence Study Comparing Single 10 mg Doses of Geneva's 10 mg Glipizide Tablets To Roerig's 10 mg Glucotrol Tablets
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type 2 Diabetes
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-07-27
Enrollment: 28
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To demonstrate the relative bioequivalency comparing Geneva's 10 mg Glipizide tablets to Roerig's 10 mg Glucotrol tablets.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 9 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Biodecision, Inc.
name: Roger D. Anderson, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05708404: Outpatient Treatment of Severe and Enduring Anorexia Nervosa
Official title: A Novel Outpatient Treatment for Patients With Severe and Enduring Anorexia Nervosa: Patient Characteristics, Treatment Goals, and Course of Treatment.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anorexia
Keywords: Anorexia nervosa
Severe and enduring anorexia nervosa
Treatment
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
First posted: 2023-02-01
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult women with severe and enduring anorexia nervosa.

Brief summary: Approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. In this study a new treatment for patients with severe and enduring anorexia nervosa was described. The treatment is flexible and aims at enhancing quality of life. The participants consisted of all referrals resulting in an assessment or treatment period at the unit between May 2017 and May 2022. The study was a registry study. Information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.


Eligibility criteria: Inclusion criteria:

* Age ≥ 18 years
* A referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the HUS Helsinki University Hospital between May 2017 and May 2022.

Primary outcomes:
measure: How the treatment goals were met
timeFrame: At the end of treatment, an average of 15.4 months
Secondary outcomes:
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: HUS Syömishäiriöyksikkö
state: Pl 282
Study officials:
affiliation: HUS Helsinki Central Hospital
name: Jaana Suokas, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03196804: A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.
Official title: A Dose Blocked-randomized, Double-blind, Placebo-controlled, Multiple Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: LG Chem
Sponsor class: INDUSTRY
First posted: 2017-06-23
Enrollment: 32
Sex: MALE
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess the safety, tolerability and pharmacokinetic characteristics of LC-28-0126 multiple iv injection in healthy male subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects between the ages of 19 and 45 years at screening.
* Subjects with BMI between 18.0(inclusive) and 27.0 kg/m2 (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive)

Exclusion Criteria:

* Participation in a clinical research study within the previous 3 months
* Regular alcohol consumption \>21 units per week.

Primary outcomes:
measure: Adverse events
timeFrame: 18 days
Secondary outcomes:
measure: Cmax
timeFrame: up to 6 days post-dose
measure: AUC
timeFrame: up to 6 days post-dose
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital, Clinical Trial Center
Study officials:
References:
citation: Kim E, Hwang I, Lee S, Oh J, Chung H, Jin M, Kim SH, Yu KS. Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects. Clin Ther. 2020 Oct;42(10):1946-1954.e2. doi: 10.1016/j.clinthera.2020.08.011. Epub 2020 Sep 24.
Clinical trial NCT01666704: Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis
Official title: A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effects of BMS-823778 on Atherosclerotic Plaque Inflammation as Measured by Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET) in Patients With Atherosclerotic Cardiovascular Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Atherosclerotic Cardiovascular Disease
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2012-08-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the effect of BMS-823778 on reducing atherosclerotic plaque inflammation


Eligibility criteria: Inclusion Criteria:

* Documented atherosclerotic cardiovascular disease or at high risk of cardiovascular event
* On stable statin dose
* Clinically stable at time of screening and randomization

Exclusion Criteria:

* Women of child bearing potential
* Medical conditions that would impact the absorption of the study drug

Primary outcomes:
measure: The effect of BMS-823778 versus placebo on carotids and/or ascending aortic will be measured by fluorodeoxyglucose (FDG) uptake in the index vessel as by positron emission tomography (PET) imaging
timeFrame: Day 168
Secondary outcomes:
measure: Structural changes in the arterial wall (absolute, percent change, and both, from baseline in four indices)
timeFrame: Day 364
measure: Safety will be measured by adverse event, vital signs, electrocardiogram, physical examinations, clinical laboratory tests and Ferriman- Gallwey scores
timeFrame: Approximately up to 60 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT06933004: Long-term Clinical Follow-up Analysis of Patients With Lumbar Disease.
Official title: Long-term Clinical Follow-up Analysis of Patients With Lumbar Disease.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lumbar Disease
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2025-04-17
Enrollment: 120
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: National Taiwan University Hospital

Brief summary: This study is a long-term follow-up of postoperative clinical outcomes in patients with lumbar spine disorders, monitoring spine implants SmartMIS Spinal Fixation System and ASA Spinal Fixation System.

Patients will be selected based on inclusion and exclusion criteria. The informed consent process will be initiated by the physician. A questionnaire-based survey will be conducted, which includes the Visual Analog Scale (VAS), Oswestry Disability Index (ODI), and Fusion Rate. Subjects will complete the same questionnaire assessments preoperatively and at 6 ± 3 months, 12 ± 3 months, and 24 ± 3 months postoperatively.

The total number of subjects to be enrolled is 120. The total duration of the study is expected to be 4 years.


Eligibility criteria: Inclusion Criteria:

1. Aged between 20 and 80 years.
2. Patients with lumbar spine disorders requiring surgical treatment.
3. Able to understand the study content after explanation, capable of expressing their experiences, and willing to sign the written informed consent form.

Exclusion Criteria:

1. Individuals with impaired decision-making capacity or from vulnerable populations.
2. Individuals who are unable or unwilling to return for follow-up assessments.

Primary outcomes:
measure: Visual Analog Scale (VAS)
timeFrame: Preoperatively and at 6 ± 3 months, 12 ± 3 months, and 24 ± 3 months postoperatively.
Secondary outcomes:
measure: Oswestry Disability Index (ODI)
timeFrame: Preoperatively and at 6 ± 3 months, 12 ± 3 months, and 24 ± 3 months postoperatively.
measure: Fusion Rate
timeFrame: Preoperatively and at 6 ± 3 months, 12 ± 3 months, and 24 ± 3 months postoperatively.
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT06830304: A Multilevel Intervention to Improve Uptake of Gastrointestinal Cancer Screening: a Cluster Randomized Clinical Trial
Official title: A Multilevel Intervention to Improve Uptake of Gastrointestinal Cancer Screening: a Cluster Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Screening Compliance
Lead sponsor: Chongqing University Cancer Hospital
Sponsor class: OTHER
First posted: 2025-02-17
Enrollment: 15000
Sex: ALL
Minimum age (years): 45
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: This study is a cluster randomized controlled trial aimed at evaluating the effectiveness of a multi-level intervention strategy in improving adherence to gastrointestinal cancer screening. Communities will be randomly assigned as the unit of randomization to either intervention or control group. The study population includes community residents aged 50-74 years. Communities in the intervention group will receive multi-level interventions including health education, patient navigation services, and appointment assistance, while communities in the control group will maintain routine screening management. All participants will be followed up for 90 days to track their endoscopy appointment and completion rates. The main research question is:

Can community-based multi-level intervention effectively improve adherence to gastrointestinal cancer screening among community residents?


Eligibility criteria: Inclusion Criteria:

* high-risk individuals of gastrointestinal cancer in 45-74 years old

Exclusion Criteria:

* Unable to give consent
* history of cancer
* severe cardiac, pulmonary, brain, or renal dysfunction or any other serious disease
* psychiatric illness
* pregnancy

Primary outcomes:
measure: Endoscopy Appointment Rate
timeFrame: From enrollment to appointment 90 days
measure: Endoscopy Completion Rate
timeFrame: From enrollment to appointment Endoscopy Completion 90 days
measure: Time to Endoscopy Completion
timeFrame: Time interval between endoscopy appointment scheduling and completion of colonoscopy.
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
state: Chongqing
Study officials:
References:
Clinical trial NCT01313104: Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer
Official title: Pilot Project for Anal Dysplasia Screening in Women With Cervical or Vulvar Dysplasia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Cervical Intraepithelial Neoplasia Grade 1
Cervical Intraepithelial Neoplasia Grade 2
Cervical Intraepithelial Neoplasia Grade 3
Recurrent Cervical Cancer
Recurrent Vaginal Cancer
Recurrent Vulvar Cancer
Stage 0 Cervical Cancer
Stage 0 Vaginal Cancer
Stage 0 Vulvar Cancer
Stage I Vaginal Cancer
Stage I Vulvar Cancer
Stage IA Cervical Cancer
Stage IB Cervical Cancer
Stage II Vaginal Cancer
Stage II Vulvar Cancer
Stage IIA Cervical Cancer
Stage IIB Cervical Cancer
Stage III Cervical Cancer
Stage III Vaginal Cancer
Stage III Vulvar Cancer
Stage IV Vulvar Cancer
Stage IVA Cervical Cancer
Stage IVA Vaginal Cancer
Stage IVB Cervical Cancer
Stage IVB Vaginal Cancer
Lead sponsor: Northwestern University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2011-03-11
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: This clinical trial studies colposcopy and high resolution anoscopy in screening for anal dysplasia in patients with cervical, vaginal, or vulvar dysplasia or cancer. Screening may help doctors find cancer cells early and plan better treatment for cancer

Detailed description: OBJECTIVES:

I. To evaluate the risk of anal dysplasia in women with cervical or vulvar dysplasia.

OUTLINE:

Patients undergo colposcopy and cervical Papanicolaou test with Human papillomavirus (HPV) test followed by anal Papanicolaou test and high resolution anoscopy. Patients with dysplastic anal lesions undergo repeat anoscopy at 3, 9, 15, and 24 months. Patients with normal anoscopy are followed up at 1 and 2 years.

Eligibility criteria: Inclusion Criteria:

* Histological confirmation of cervical, vaginal or vulvar intraepithelial neoplasia or cancer are included
* Individuals treated with prior radiation therapy and/or chemotherapy are allowed
* Women with high-grade dysplasia (carcinoma in situ) are eligible, regardless of their dysplasia free interval
* HIV-positive (Human Immunodeficiency Virus) and HIV-negative women will be enrolled; HIV testing will not be performed as part of the study

Exclusion Criteria:

* Women who are not able to consent are excluded

Primary outcomes:
measure: Risk of anal dysplasia in women with cervical or vulvar dysplasia
timeFrame: Over 2 years
measure: HPV (Human Papillomavirus) status
timeFrame: Over 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Northwestern University
name: Amy Halverson
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02299804: A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo
Official title: A Multicenter, Double-Blind, Phase Ⅱ Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Vertigo
Lead sponsor: Sihuan Pharmaceutical Holdings Group Ltd.
Sponsor class: INDUSTRY
First posted: 2014-11-24
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A Multicenter, Double-Blind, Placebo Controlled, Phase Ⅱa clinical trial to enroll 120 patients with Vertigo Caused By Posterior Circulation Infarction during 7 days, then to evaluate the efficacy of different dose of Levophencynonate Hydrochloric, and provide the effective dosage for phase IIb clinical study, to study the safety of Levophencynonate Hydrochloric.

Detailed description: This study will conduct in 15 sites to enrolled 120 patients with vertigo under 7 days treatment and 7 days follow-up. The study includes three arms: high dose, low dose and placebo control.To observe the efficacy by change of vertigo severity and duration,and safety by vital sign,adverse event,etc.

Eligibility criteria: Inclusion Criteria:

1. At the age more than 18 years old male or female;
2. Patients with vertigo caused by Posterior Circulation Infarction.
3. Patients diagnosed Posterior Circulation Infarction based on the criteria of Posterior Circulation Ischemia of America;
4. Meet the diagnose criteria of vertigo: Visual Motion (External Vertigo), or Rotation, Swing, Lift and Tilt Sensation (Internal Vertigo);
5. Ability to sign the statements of informed consent;

Exclusion Criteria:

1. Female patients having Pregnant, Lactating or Birth plan recently;
2. Non-posterior circulation infarction patients;
3. Vertigo caused by any other diseases;
4. Long-term alcohol abuse, or drug abuse;
5. Been in critical condition, difficult to make a precise evaluation of efficacy and safety of new drugs;
6. History of allergies on Levophencynonate Hydrochloric or these compositions;
7. Participation in another clinical trial in three months;
8. Investigator thought that should be excluded due to other reason;

Primary outcomes:
measure: The duration of vertigo
timeFrame: up to 7 days
Secondary outcomes:
measure: Vertigo severity improved（VAS score）
timeFrame: up to 7 days
measure: Nerve function improved（NIHSS/MRS score）
timeFrame: up to 7 days
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital Shanghai Jiaotong University School of Medicine
state: Shanghai
Study officials:
affiliation: RenJi Hospital
name: Yansheng Li, PHD
role: PRINCIPAL_INVESTIGATOR
References: